Leuko
Private Company
Total funding raised: $2.5M
Overview
Leuko is a Barcelona-based medtech startup, founded in 2017 as a spin-out from MIT, focused on non-invasive blood cell monitoring. Its flagship product, PointCheck™, is a portable, at-home device designed to screen for severe neutropenia (dangerously low white blood cells) by imaging capillaries in the finger, eliminating the need for blood draws. The company aims to improve quality of life and clinical outcomes for chemotherapy patients by enabling frequent monitoring and early intervention. Leuko is in the development and clinical validation stage, having won several awards and secured non-dilutive funding, but its device remains investigational and pre-commercial.
Technology Platform
Optical imaging and AI platform for non-invasive analysis of blood cells in superficial capillaries, focused on detecting severe neutropenia.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Direct competition for non-invasive white cell counting is limited, but Leuko competes with the entrenched standard of invasive blood draws and lab analysis. Potential future competitors include other optical/AI hematology startups or large diagnostic firms (e.g., Sysmex, Abbott) developing point-of-care solutions.